| 產(chǎn)品名稱 |
CKMM 14.52 |
| 商品貨號 |
B164262 |
| Organism |
Rattus norvegicus (B cell); Mus musculus (myeloma), rat (B cell); mouse (myeloma) |
| Tissue |
spleen |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
The antibody reacts preferentially with CK-MM, but cross-reacts with CK-MB. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with Sp2/0-Ag14 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against human CK-MM (creatine kinase - MM) |
| Cellular Products |
immunoglobulin; monoclonal antibody; against human CK-MM (creatine kinase - MM) |
| Comments |
Animals were immunized with human creatine kinase - MM. Spleen cells were fused with Sp2/0-Ag14 myeloma cells. The antibody reacts preferentially with CK-MM, but cross-reacts with CK-MB. Binding of the antibody inhibits the enzyme activity of both CK-MM and CK-MB. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium.
Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml. Interval: Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation |
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype |
IgG1 kappa |
| Name of Depositor |
Eastman-Kodak Co. |
| Deposited As |
rat (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Daiss JL. Blend of monoclonal antibodies. US Patent 4,950,592 dated Aug 21 1990
|
